What question did this study set out to answer?

To quantify the incidence of new mental health diagnoses and psychotropic medication dispensing in pediatric survivors of PARDS within one year post-discharge.

March 26, 2026

1739: New Mental Health Diagnoses and Psychotropic Med Starts in Year Following Pards

Puntos clave

To quantify the incidence of new mental health diagnoses and psychotropic medication dispensing in pediatric survivors of PARDS within one year post-discharge.
Analyzed IBM Marketscan Commercial and Medicaid claims database from 2016-2023.
Included children aged 6-18 years with PARDS index admission.
Assessed first inpatient or outpatient claims for anxiety, PTSD, depression, suicidality, or other disorders.
Evaluated psychotropic medication dispensing within 90 and 365 days of discharge.
Utilized AI for data analysis and abstract refinement.
36.6% of survivors had a mental health diagnosis at discharge.
13% developed new anxiety, 8.4% new depression, 4.9% new suicidality/self-harm, and 36% new unspecified disorders within a year.
3.3% were hospitalized due to suicidality or suicide attempts.
20.2% initiated psychotropic medication within 90 days; antidepressants were most common at 15.0%.
At one year, 27.3% had received any psychotropic prescription, with 15.9% prescribed an antidepressant.

Resumen

Introduction: Pediatric survivors of acute respiratory distress syndrome (PARDS) face persistent physical and psychosocial sequelae, yet post-discharge mental-health outcomes remain undefined. Recent U.S. commercial-claims data showed 8% of children admitted to an ICU developed a new mental health diagnosis within 12 months. We aimed to quantify the incidence of new mental health diagnoses and psychotropic medication dispensing in the year following PARDS hospitalization. Methods: We analyzed the 2016-2023 IBM Marketscan Commercial and Medicaid claims database. Children aged 6–18 years with an index admission meeting a validated ICD10 PARDS algorithm and surviving to discharge were included. Patients with < 3 months continuous insurance coverage post-discharge were excluded. Outcomes were (1) first inpatient or outpatient claim containing ICD10 codes for anxiety or PTSD (F41.x, F43), depression (F3234, F39), suicidality/self-harm (R45.8, T14.91, X7183), or other/unspecified disorders (F99), and (2) first dispensing of an antidepressant, antipsychotic, or other psychotropic within 90 and 365 days. For mental health diagnoses, patients could develop more than one disease category illness. AI was used in abstract refinement and stats program coding. Results: Among 7,097 survivors (median age 14 y; IQR 9-17; median LOS 10 d), 36.6% (n=2,598) carried a mental health diagnosis of interest at discharge (anxiety 5.3%, depression 4.9%). In the year following PARDS, 13% (n = 895) had a new anxiety diagnosis, 8.4% (n=588) new depression, 4.9% (n=343) new suicidality/self-harm, and 36% (n=2,515) had a new other/unspecified mental health disorder. Suicidality or suicide attempt resulted in hospitalization in 3.3% (n=231) patients. Psychotropic medication was initiated within 90 days in 20.2% (n= 1,422) of survivors with antidepressants (15.0%, n=717) the most common medication initiated. At one-year after discharge, 27.3% (n=1,934) had received any psychotropic prescription and 15.9% (n=1,128) an antidepressant. Conclusions: New mental health diagnoses in survivors of PARDS are common. Access to mental health care both at discharge and in the year following PARDS should be a cornerstone of post ICU care. Future work is needed to identify modifiable PARDS course factors that may contribute to mental health diagnoses.

Preguntar a la IA

Me gusta

Guardar